Recombinant

Anti-Androgen Receptor antibody [SP107] - N-terminal (ab105225)

Overview

  • Product name
    Anti-Androgen Receptor antibody [SP107] - N-terminal
    See all Androgen Receptor primary antibodies
  • Description
    Rabbit monoclonal [SP107] to Androgen Receptor - N-terminal
  • Host species
    Rabbit
  • Tested applications
    Suitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Dog, Pig
  • Immunogen

    Synthetic peptide within Human Androgen Receptor aa 300-400 (N terminal). The exact sequence is proprietary.
    Database link: P10275

  • Positive control
    • IHC-P: Human prostate carcinoma, prostate adenocarcinoma, breast ductal carcinoma, skin squamous cell carcinoma, uterus, endometrial adenocarcinoma, breast, cervix, placenta, prostate, testis, bladder transitional cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma and ovarian adenocarcinoma tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab105225 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/400. Boil tissue section in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at RT for 20 min.

Target

  • Function
    Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
    Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
  • Tissue specificity
    Isoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
  • Involvement in disease
    Androgen insensitivity syndrome
    Spinal and bulbar muscular atrophy X-linked 1
    Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
    Androgen insensitivity, partial
  • Sequence similarities
    Belongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • Domain
    Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
  • Post-translational
    modifications
    Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
    Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
  • Cellular localization
    Nucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
  • Information by UniProt
  • Database links
  • Form
    There are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
  • Alternative names
    • AIS antibody
    • ANDR_HUMAN antibody
    • Androgen nuclear receptor variant 2 antibody
    • Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody
    • Androgen receptor antibody
    • androgen receptor splice variant 4b antibody
    • AR antibody
    • AR8 antibody
    • DHTR antibody
    • Dihydro testosterone receptor antibody
    • Dihydrotestosterone receptor (DHTR) antibody
    • Dihydrotestosterone receptor antibody
    • HUMARA antibody
    • HYSP1 antibody
    • KD antibody
    • Kennedy disease (KD) antibody
    • NR3C4 antibody
    • Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody
    • Nuclear receptor subfamily 3 group C member 4 antibody
    • SBMA antibody
    • SMAX1 antibody
    • Spinal and bulbar muscular atrophy (SBMA) antibody
    • Spinal and bulbar muscular atrophy antibody
    • Testicular Feminization (TFM) antibody
    • TFM antibody
    see all

Images

  • Formalin-fixed, paraffin-embedded human prostate carcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human breast ductal carcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human skin squamous cell carcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human uterus tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human endometrial adenocarcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human breast tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human cervix tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human placenta tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human testis tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human bladder transitional cell carcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human hepatocellular carcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human lung adenocarcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human lung squamous cell carcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human pancreatic adenocarcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human ovarian adenocarcinoma tissue stained for Androgen Receptor with ab105225 at 1/400 dilution in immunohistochemical analysis.

References

ab105225 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab105225.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up